Equities research analysts forecast that BioXcel Therapeutics Inc (NASDAQ:BTAI) will post earnings of ($0.34) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for BioXcel Therapeutics’ earnings. The company is scheduled to report its next quarterly earnings results on Friday, February 8th.
According to Zacks, analysts expect that BioXcel Therapeutics will report full-year earnings of ($1.20) per share for the current financial year. For the next financial year, analysts forecast that the company will post earnings of ($2.03) per share. Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for BioXcel Therapeutics.
BioXcel Therapeutics (NASDAQ:BTAI) last announced its quarterly earnings results on Friday, November 9th. The company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.05).
NASDAQ:BTAI traded up $0.04 during midday trading on Thursday, hitting $5.61. 11,702 shares of the company were exchanged, compared to its average volume of 330,011. BioXcel Therapeutics has a fifty-two week low of $2.41 and a fifty-two week high of $14.79.
In other BioXcel Therapeutics news, Director Peter Mueller acquired 8,795 shares of the company’s stock in a transaction on Friday, December 7th. The shares were bought at an average cost of $5.01 per share, for a total transaction of $44,062.95. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders acquired 19,152 shares of company stock worth $95,778.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Artemis Investment Management LLP boosted its holdings in shares of BioXcel Therapeutics by 1.3% in the third quarter. Artemis Investment Management LLP now owns 1,254,853 shares of the company’s stock valued at $9,700,000 after acquiring an additional 16,358 shares in the last quarter. Creative Planning purchased a new stake in shares of BioXcel Therapeutics in the third quarter valued at about $102,000. Point72 Asset Management L.P. boosted its holdings in shares of BioXcel Therapeutics by 10.7% in the second quarter. Point72 Asset Management L.P. now owns 65,809 shares of the company’s stock valued at $605,000 after acquiring an additional 6,358 shares in the last quarter. Finally, BlackRock Inc. purchased a new stake in shares of BioXcel Therapeutics in the second quarter valued at about $137,000. Institutional investors own 20.79% of the company’s stock.
About BioXcel Therapeutics
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Featured Story: How to interpret a stock’s beta number
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.